Q-omics provides the consensus-scored C1orf115 profile across patient tissues and cancer cell-line models. C1orf115 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C1orf115 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, C1orf115 RNA expression shows 21,935 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where C1orf115 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1orf115 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1orf115 survival associations across molecular data types. C1orf115 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1orf115 RNA expression–survival associations across cancer types. High C1orf115 expression shows unfavorable associations in KICH, ACC and UVM, but favorable associations in KIRC, OV and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C1orf115 RNA expression.
This table summarizes C1orf115 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C1orf115. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1orf115 shows lower tumor expression in KICH, COAD, KIRP, KIRC, LUAD and UCEC. The KICH box plot shows higher C1orf115 RNA expression in normal versus tumor tissue (log2 FC = −3.968, t-test p < 0.001).
This table shows molecular features associated with C1orf115 in patient tissues and cancer cell lines. In patient samples, C1orf115 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, C1orf115 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
